Courtesy of Dr. Carlos Fava. About 12% of patients >75 years old have aortic stenosis. In 3%-4% of them, such disease is severe. Transcatheter aortic valve replacement (TAVR) has already proven to be beneficial for extreme-, high-, and intermediate-risk patients. Regarding low-risk patients, we currently have different analyses; two of them are randomized and their results are<a href="https://solaci.org/en/2019/09/30/very-encouraging-results-for-tavr-in-low-risk-patients/" title="Read more" >...</a>
TAVR and Pacemakers, New Strategies
Courtesy of Dr. Carlos Fava. TAVR has been shown beneficial and is constantly being advanced onto lower risk populations, but at present, it is limited (perhaps most importantly in aortic tricuspid valves) by the need for permanent pacemaker implantation (PPMI), especially when it comes to self-expandable valves, as the latest study on low risk populations<a href="https://solaci.org/en/2019/09/30/tavr-and-pacemakers-new-strategies/" title="Read more" >...</a>
TAVR in Bicuspid Has the Same Results in Surgery at Hospital Level
Courtesy of Dr. Carlos Fava. Bicuspid aortic stenosis patients (bicuspid AS) represent a small group and have not been included in the larger transcatheter aortic valve replacement (TAVR) studies, since they present different morphology and asymmetric calcification, which might come along with more paravalvular leak and less accurate positioning. Between 2012 and 2016, 475,315 patients<a href="https://solaci.org/en/2019/09/24/tavr-in-bicuspid-has-the-same-results-in-surgery-at-hospital-level/" title="Read more" >...</a>
FDA Expands TAVR Indication to Low-Risk Patients
Both the self-expandable valve Evolut R and its direct competitor, balloon-expandable valve Sapien 3, received the authorization to be indicated for low-risk patients in a long-awaited announcement made on August 16th, 2019. The US Food and Drug Administration (FDA) has approved and expanded the indication for the Evolut series (Medtronic) and the Sapien 3 and<a href="https://solaci.org/en/2019/08/21/fda-expands-tavr-indication-to-low-risk-patients/" title="Read more" >...</a>
II International Symposium on Innovations in the Treatment of Coronary Artery Disease and Structural Heart Disease
The II International Symposium on Innovations in the Treatment of Coronary Artery Disease and Structural Heart Disease will take place on July 31st, 2019 at the Syrian-Lebanese Hospital in São Paulo. This event seeks to provide a better understanding of indications and clinical and interventional strategies for complex heart conditions, such as left main coronary<a href="https://solaci.org/en/2019/07/15/ii-international-symposium-on-innovations-in-the-treatment-of-coronary-artery-disease-and-structural-heart-disease/" title="Read more" >...</a>
The Most Read Articles in Interventional Cardiology in SOLACI
1- What to Do with Blood Pressure Levels Between 130/80 and 139/89 mmHg The decision to be made with a treatment-free patient with systolic blood pressure over 160 mmHg or diastolic blood pressure over 100 mmHg is an easy one. All guidelines agree: treatment should be started immediately alongside lifestyle changes. Read also HERE 2- Low-Risk<a href="https://solaci.org/en/2019/07/02/the-most-read-articles-in-interventional-cardiology-in-solaci/" title="Read more" >...</a>
Pulmonary Hypertension: No Reason for TAVR Contraindication
In most severe aortic stenosis patients with pulmonary hypertension, transcatheter aortic valve replacement (TAVR) reduced pulmonary systolic pressure. There patients presented lower risk and lower all-cause mortality at short, median and long term. This data show that pulmonary hypertension should not be a TAVR contraindication. Pulmonary hypertension is common among TAVR patients. The most frequent<a href="https://solaci.org/en/2019/06/14/pulmonary-hypertension-no-reason-for-tavr-contraindication/" title="Read more" >...</a>
Low-Risk TAVR Trending in All Papers
Transcatheter aortic valve replacement (TAVR) in low-risk patients with symptomatic severe aortic stenosis appears to be safe at one year. In a follow-up using computerized tomography (TC), hypoattenuated leaflet thickening was observed in a minority of patients, but it did not have a long-term hemodynamic impact. It should be noted that the management strategy for<a href="https://solaci.org/en/2019/06/13/low-risk-tavr-trending-in-all-papers/" title="Read more" >...</a>
Safe for 80-Year-Olds. Should Nonagenarians be Withheld from TAVR?
According to this large global registry, mortality after transcatheter aortic valve replacement (TAVR) is twice as high in nonagenarians as against the “younger” group (90 patients. Additionally, risk scores cannot be trusted given that on the one hand they were designed for patients with planned surgery, and on the other hand, they included few patients<a href="https://solaci.org/en/2019/06/11/safe-for-80-year-olds-should-nonagenarians-be-withheld-from-tavr/" title="Read more" >...</a>
The Most Read Articles of may in Interventional Cardiology
1- Surprising EXCEL Outcomes in Diabetics with Main Left Stenosis This study especially designed to compare PCI vs. CABG in patients with left main coronary artery disease and low to intermediate Syntax score showed that 30-day and 3 -year outcomes of PCI with everolimus eluting stents vs CABG were consistent both in diabetic and non-diabetic<a href="https://solaci.org/en/2019/06/06/the-most-read-articles-of-may-in-interventional-cardiology/" title="Read more" >...</a>